Pemphigus Vulgaris Companies

Disclaimer: List of key companies in no particular orderLatest Pemphigus vulgaris Companies Update

• 
  Jan 2023: The directSTIM Deep Brain Stimulation (DBS) system from Switzerland-based Aleva Neurotherapeutics has been granted the CE mark. The precise current steering towards the intended structural location made possible by the DBS system technology increases the efficacy of DBS and lowers the possibility of adverse effects. The only technological company to obtain a CE mark for a DBS system is reportedly Aleva Neurotherapeutics. Through a post-market clinical follow-up study, it will start direct sales in a few European neurological clinics. Their Deep Brain Stimulation System combines the best directional electrode technology with a user-friendly patient programming interface to help functional neurosurgery teams treat patients more effectively.

• 
  June 2023: According to the business, Argenx SE's under-the-skin injection has been licensed by the US Food and Drug Administration to treat generalized myasthenia gravis, a genetic illness that weakens muscles. The medication, known as Vyvgart Hytrulo, is anticipated to go on sale in the United States the following month and has a list price of $15,773. The drug's intravenous version, Vyvgart, was approved by the FDA in 2021. However, the manufacturer anticipates that an under-the-skin version will provide more convenient administration than an intravenous infusion. Over $400 million was made in sales globally by Vyvgart last year. The chronic neuromuscular condition known as generalised myasthenia gravis (gMG) is brought on by an aberrant immune response that weakens the muscles in various body areas. The drug was approved based on late-stage research that demonstrated Vyvgart Hytrulo was non-inferior to Vyvgart in lowering the levels of a specific type of antibody while managing the autoimmune disease.

• Almirall, SA


• Argenx SE


• Biogen Inc.


• F. Hoffmann-La Roche


• Syntimmune


• Pfizer Inc.


• Novartis AG


• Sanofi


• Janssen Global Services, LLC


• Principia Biopharma